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Mutant GlialCAM Causes Megalencephalic Leukoencephalopathy
with Subcortical Cysts, Benign Familial Macrocephaly,
and Macrocephaly with Retardation and Autism
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Gert C. Scheper,3 Albert Martı´nez,8 Rau´l Este´vez,1,4,10,* and Marjo S. van der Knaap3,10,*
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a leukodystrophy characterized by early-onset macrocephaly and
delayed-onset neurological deterioration. RecessiveMLC1mutations are observed in 75% of patients with MLC. Genetic-linkage studies
failed to identify another gene. We recently showed that some patients withoutMLC1mutations display the classical phenotype; others
improve or become normal but retain macrocephaly. To find another MLC-related gene, we used quantitative proteomic analysis of
affinity-purified MLC1 as an alternative approach and found that GlialCAM, an IgG-like cell adhesion molecule that is also called Hep-
aCAM and is encoded by HEPACAM, is a direct MLC1-binding partner. Analysis of 40 MLC patients without MLC1mutations revealed
multiple different HEPACAM mutations. Ten patients with the classical, deteriorating phenotype had two mutations, and 18 patients
with the improving phenotype had one mutation. Most parents with a single mutation had macrocephaly, indicating dominant inher-
itance. In some families with dominant HEPACAM mutations, the clinical picture and magnetic resonance imaging normalized, indi-
cating that HEPACAM mutations can cause benign familial macrocephaly. In other families with dominant HEPACAM mutations,
patients had macrocephaly and mental retardation with or without autism. Further experiments demonstrated that GlialCAM and
MLC1 both localize in axons and colocalize in junctions between astrocytes. GlialCAM is additionally located in myelin. Mutant Glial-
CAM disrupts the localization of MLC1-GlialCAM complexes in astrocytic junctions in a manner reflecting the mode of inheritance. In
conclusion, GlialCAM is required for proper localization ofMLC1.HEPACAM is the second gene found to bemutated inMLC. Dominant
HEPACAM mutations can cause either macrocephaly and mental retardation with or without autism or benign familial macrocephaly.Introduction
Megalencephalic leukoencephalopathy with subcortical
cysts (MLC, MIM 604004) is a leukodystrophy with auto-
somal-recessive inheritance.1 Patients develop macroce-
phaly during the first year of life. After several years, there
is evidence of slow neurological deterioration, including
cerebellar ataxia, spasticity, epilepsy, and mild cognitive
decline. From early on, magnetic resonance imaging
(MRI) reveals diffuse signal abnormality and swelling of
the brain white matter and subcortical cysts (Figure S1,
available online).1 In follow-up exams, the white matter
abnormalities remain and atrophy ensues.1 A brain biopsy
from an MLC patient showed extensive myelin vacuola-
tion, mainly affecting the outer myelin layers, which
causes the swollen appearance of the white matter.2 In
2001, we demonstrated that mutations in MLC1 (MIM
605908) cause MLC.3 MLC1 mutations are found in
approximately 75% of the MLC patients.4 MLC1 is an olig-
omeric membrane protein that is expressed almost exclu-
sively in the brain. It has some degree of homology to
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brospinal fluid (CSF)-brain barriers, Bergmann glia, and
main axonal tracts.5–7 Thus far, the physiological role of
MLC1 has remained unknown, and a suggested role in
ion transport has not been confirmed.3,5,8
In some families, members with MLC do not have
MLC1 mutations, and these families do not show linkage
to the MLC1 locus, indicating that mutations in at least
one other gene are involved in MLC,9,10 but genetic-
linkage studies failed to identify another disease gene.
We recently described two distinct phenotypes among
MLC patients without MLC1 mutations.11 The classical
phenotype retains typical clinical and MRI features, as
seen in patients with MLC1 mutations.1,11 The second,
improving phenotype is initially the same as the classical
phenotype but lacks clinical deterioration and shows
major improvement or normalization of the MRI abnor-
malities (Figure S1).11
Because of the unsuccessful genetic-linkage studies and
the possibility of further genetic heterogeneity, we decided
to use alternative strategies to identify eligible candidate
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Material and Methods
The studies on human samples were performed with approval
of the institutional review board, VU University Medical Center,
Amsterdam, and informed consent from the families. The animal
experimental protocols were approved by the Animal Care and
Ethics Committee of the University of Barcelona. Protocols for
the use and manipulation of the animals were approved by the
Government of Catalonia.Biochemistry
Preparation of Source Material
Plasma membrane-enriched protein fractions were prepared from
pools of freshly isolated whole rat or mouse brains according to
the procedure used in Zolles et al.12 For solubilization, the
prepared membrane vesicles were resuspended in ComplexioLyte
buffer 47a (at 0.8 mg protein/ml, LOGOPHARMGmbH, Germany;
with protease inhibitors added) and incubated for 30 min at 4C;
nonsoluble components were removed afterward by ultracentrifu-
gation (10 min at 150.000 3 g). Efficiency of solubilization was
determined by immunoblot analysis of SDS-PAGE-resolved
aliquots of solubilisate and pellet fractions. Polyvinylidene fluo-
ride (PVDF) membranes were probed with rabbit polyclonal anti-
bodies (a-N1 or a-NH, 1:10.000, see below), stained with goat
anti-rabbit-HRP (Santa Cruz Biotechnologies, USA) and developed
with ECLþ (GE Healthcare, USA).
Preparation of Antibodies
Immune sera against N-terminal mouse MLC1 peptides (a-N1 and
a-N2) and the a-NH (anti-N-terminus of human MLC1) antibody
were generated and characterized previously.5,7,13 The a-NH
also recognizes mouse/rat MLC1. Immune sera against a mouse
GlialCAM synthetic peptide (QRIREQDESGQVEISA), correspond-
ing to amino acids 403–418 of GlialCAM, were raised in rabbits
with the help of the services provided by Eurogentec. The peptide
was coupled to keyhole limpet hemocyanin via a cysteine residue
that has been added to the N-terminal end of the peptide. After
three boosts of immunization, the antisera were affinity purified
with the peptide covalently coupled to Sulpholink (Pierce). The
polyclonal antibody was tested by immunoblotting, immunofluo-
rescence, and immunoprecipitation on HeLa cells expressing
human GlialCAM and on mouse brain tissue.
Affinity Purification
For each experiment, 1.5 ml freshly prepared solubilisate (rat or
mouse) was incubated for 2 hr at 4C with 20 mg of the respective
immobilized antibody13 (a-N1, a-N2 a-NH, a-GlialCAM, IgG ¼
control rabbit IgG [Upstate, USA]). After a brief washing (twice
for 5 min each time) with ComplexioLyte 47a, bound proteins
were eluted with Laemmli buffer (dithiothreitol [DTT] was added
after elution). Eluates were then briefly run on SDS-PAGE gels
followed by silver staining and tryptic digestion. During these
experiments, samples were taken for immunoblot analysis with
the indicated MLC1 and GlialCAM antibodies.
Preparation of Myelin
Myelin was prepared as described previously.14 Two brains from 6-
to 8-week-old wild-type mice were homogenized in 20 volumes of
homogenization buffer (0.32M sucrose in 10mMHEPES [pH 7.4])
with five strokes with a loose pestle and seven strokes with a tight
pestle. The homogenate was layered over 0.85 M sucrose, centri-
fuged at 25,000 rpm for 30 min in a swinging bucket rotor.
Proteins located in the interphase were removed, resuspended in
10 volumes of water, and centrifuged at 25,000 rpm for 15 min.The AmThe pellet was twice cleansed of sucrose by water suspension
and centrifugation. Then, pellets were suspended again in homog-
enization buffer and layered over 0.85 M sucrose and centrifuged
at 25,000 rpm for 30 min. The interphase layer was again sus-
pended in water, centrifuged for 15 min, and resuspended in
10mMHEPES buffer (pH 7.4) containing 1% TritonX-100. Protein
was quantified by bicinchoninic acid, and 20 mg was used for SDS-
PAGE and immunoblot analyses.Mass Spectrometric Analysis
Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis
Stained gel lanes were excised in two parts (upper and lower), and
proteins were digested with trypsin according to the procedure
described previously.15 Extracted peptides dissolved in 0.5% tri-
fluoroacetic acid were loaded on a precolumn (C18 PepMap100,
5 mm; Dionex, Idstein, Germany) of an UltiMate 3000 HPLC (Dio-
nex, Idstein, Germany). An aqueous organic gradient was then
applied for elution and separation of peptides on a 75 mm column
packed with C18 beads (ReproSil-Pur 120 ODS-3; Dr. A Maisch,
Ammerbuch-Entringen, Germany) and directly electrosprayed
into an LTQ-FT mass spectrometer (Thermo Scientific, Bremen,
Germany; ion source: Proxeon, Odense, Denmark). Each scan
cycle consisted of one FTMS full scan and up to five ITMS depen-
dent MS/MS scans of the five most intense ions. Dynamic
exclusion (30 s, mass width 20 ppm) and monoisotopic precursor
selection were enabled. Using Mascot (Matrix Science, UK) we
searched extracted MS/MS spectra against the Swiss-Prot database
(Mammalia). We allowed common variable modifications and one
missed tryptic cleavage; peptide tolerance was5 10 ppm and MS/
MS tolerance was 5 0.8 Da. Proteins that (1) were identified by
only one specific MS/MS spectrum or (2) presented exogenous
contaminations like keratins, trypsin, or immunoglobulins were
not considered in further evaluations.
Protein Quantification
We used two previously detailed protein quantificationmethods16
that are both based on liquid chromatography-mass spectrometry
(LC-MS) peptide signal intensities extracted (as peak volumes
[PVs]; m/z tolerance was 6 ppm) and aligned (between individual
LC-MS runs by their retention times; tolerance was 8%) with MS
Inspect (Computational Proteomics Laboratory, Fred Hutchinson
Cancer Research Center, Seattle, WA, USA) and in-house written
software. The relative quantity of a protein in affinity purification
sample versus control was calculated as a median of consistent
peakvolume ratios of respective peptides (rPV). Ensuring the signif-
icanceof rPVs, required that at least twopeptide ratios had assigned
PVs totaling 100,000 volume units. Proteins were regarded as
specifically (co-) purified when their rPV values were higher than
10.Themolar amountsofdifferentproteinswere comparedbyusing
abundancenorm values (as in Figure 1), calculated as the sum of all
assigned peak volumes (totalPV) divided by the number of MS-
accessible amino acids (sequence of tryptic peptides with masses
between 740 and 3000 Da under the MS settings used).Genetic Analysis
The diagnosis of MLC was established by MRI criteria.1 In those
MLC patients in whom we found no mutations in MLC1 by
sequence analysis of genomic DNA, as well as analysis of MLC1
cDNA and MLPA, we analyzed HEPACAM (hepatic and glial cell
adhesion molecule, MIM 611642), the gene encoding GlialCAM.
HEPACAM primers were designed with ExonPrimer (Table S1).
Accession numbers of the reference sequences are NM_152722.4erican Journal of Human Genetics 88, 422–432, April 8, 2011 423
Figure 1. Proteomic Identification of GlialCAM as a Major Binding Partner of MLC1
(A) Affinity purification (AP) strategy based on efficient MLC1 solubilization (left) as visualized by immunoblot analysis of SDS-PAGE-
resolved samples from rat brainmembrane, solubilisate, and pellet (stained with anti-MLC1 (a-N1)) and three antibodies (right) directed
against N-terminal epitopes of MLC1. Similar results were obtained when two different antibodies were applied or when the three anti-
bodies were applied simultaneously, confirming the specificity of the proteomics data.
(B and C) Evaluation ofMLC1 affinity purifications with the indicated antibodies. (B) 2D plot of protein abundances determined bymass
spectrometry (for abundancenorm values see Material and Methods) of AP with a-N1 (from rat brain) versus AP with a-NH (from mouse
brain). Only proteins specifically enriched (more than 10-fold of the amount in the respective IgG control) and identified in both APs are
shown (as dots). Note the distinct quantitative correlation of GlialCAM with MLC1. Pearson correlation of GlialCAM and MLC1 abun-
dancenorm values across all three APs and controls is r¼ 0.96. (C) Immunoblot analysis of APs with the indicated antibodies stained with
anti-MLC1 (a-N1; upper) and anti-GlialCAM (lower); lanes resolve aliquots of solubilisate before (S) and after AP (U), of eluates from APs
(E), and of corresponding IgG control APs (C).
(D) Immunoblots showing specific copurification of MLC1 in an AP with anti-GlialCAM (samples and antibodies labeled as before). ‘‘–’’
indicates no sample was loaded.(mRNA) and NT_033899.8 (gDNA). PCR amplification of exons 1–
6 of HEPACAM and their surrounding intronic regions was carried
out with Platinum TAQ DNA Polymerase according to the manu-
facturer’s instructions (Invitrogen). For exon 7, which has a very
high-GC content, Platinum TAQ DNA-polymerase (Invitrogen)
was used in combination with 5X AccuPrime GC-Rich Buffer A
(Invitrogen). The PCR products were analyzed by cycle sequencing
on an ABI3730 Genetic Analyzer (Applied Biosystems) with the
same primers used for PCR amplification, with the exception of
the forward primer of exon 1. The resulting chromatograms
were analyzed with Sequence Pilot (JSI Medical Systems Gmbh)
with ENSG00000165478 as reference sequence.424 The American Journal of Human Genetics 88, 422–432, April 8, 2Immunofluorescent and Electron Microscopic Studies in Tissue
Tissue immunohistochemistry was performed as previously
described.5,7 For electron microscopic (EM) studies, small human
cerebellum samples were obtained postmortem, fixed in 4% para-
formaldehyde and 0.1% glutaraldehyde in 0.12 M phosphate
buffer, andprocessed. Theywere cryoprotected gradually in sucrose
and cryofixed by immersion in liquid propane. Freeze substitution
was performed at 90C during 3 days in an Automatic Freeze
SubstitutionSystem(AFS, Leica);methanol containing0.5%uranyl
acetate was used as a substitution medium. Infiltration was carried
out in Lowicryl HM20 at 50C and then polymerized with UV
lamps. Ultrathin sections were collected and processed for011
postembedding immunostaining. For double immunostaining,
grids were incubated with rabbit anti-N4-human MLC1 (1:10)
and mouse anti-GlialCAM (1:10) antisera. The binding of primary
antibodies was visualized by incubating with goat anti-rabbit or
goat anti-mouse secondary antibodies conjugated to either 12 or
18 nm gold particles (British BioCell, International). In control
experiments, the primary antibodies were omitted—no immuno-
gold labeling occurred under these conditions.
Primary Culture and Adenoviral Transduction
Rat primary astrocytes were prepared as described previously13
with somemodifications. Cortex and hippocampus were removed
from newborn (1 to 3 days old) Sprague Dawely rats (Charles
River). Cerebral cortices were dissected and the meninges were
carefully removed in cold sterile 0.3% BSA and 0.6% glucose in
PBS. The tissue was trypsinized for 10 min at 37C and mechani-
cally dissociated in complete Dulbecco’s modified Eagle’s medium
(DMEM; with 10% heat-inactivated fetal bovine serum [Biological
Industries], 1% penicillin/streptomycin [Invitrogen] and 1% gluta-
mine [Invitrogen] plus 40 U/ml DNase I [Sigma]) through a small
bore fire-polished Pasteur pipette. The cell suspension was pelleted
and resuspended in fresh complete DMEM, filtered through a 100-
mm nylon membrane (BD Falcon) and plated into 75 cm2 cell-
culture flasks (TPP). When the mixed glial cells reached conflu-
ence, contaminating microglia, oligodendrocytes, and precursor
cells were dislodged by mechanical agitation and removed as
previously described.17
Astrocytes were plated in 6-well plates at a density of 4 3 105
cells per well or in poly-D-lysine-coated coverslips at 7.5 3 104
cells per 24-well plate. Medium was changed every 3 days. To
increase the expression of MLC1 and GlialCAM detection at the
plasma membrane (data not shown), we arrested astrocytic
cultures in the cell cycle by addition of 2 mM cytosine b-D-arabino-
furanoside (AraC, Sigma). Cultured astrocytes were identified by
their positive GFAP staining (Dako).
Construction of adenovirus expressing wild-type HA-tagged
human MLC1 has been described.13 In a similar manner, we con-
structed and produced adenoviruses expressing three copies of the
flag epitope fused to wild-type human GlialCAM or to human
GlialCAM containing either the recessive mutations p.Arg92Gln,
p.Arg98Cys, and p.Ser196Tyr or the dominant mutations
p.Arg92Trp and p.Gly89Asp.
To infect astrocytes, we added adenoviruses at multiplicity of
infection (MOI) 3 and kept them overnight at 37C. Cells were
washed, and then fresh medium was added. Astrocytes were incu-
bated at 37C until they were processed.Results
MLC1-Interacting Proteins
We used a method of quantitative proteomic analysis of
affinity-purified MLC1 to identify candidate genes for
MLC. Independent affinity-purification experiments with
MLC1 were performed with solubilized brain membranes
and three different antibodies directed against peptides
from theMLC1N terminus (Figure 1A). Protein abundance
determined by quantitative mass spectrometry identified
HepaCAM, more correctly called GlialCAM,18 as the
protein with the second highest yield (after MLC1) in all
purifications (Figure 1B and Figure S2A). ImmunoblotsThe Amwith antibodies against GlialCAM (Figure S3) demon-
strated that the protein was present in all purifications
with all different MLC1 antibodies (Figure 1C). Not all
GlialCAM coimmunoprecipitated with MLC1
(Figure 1C), possibly because not all GlialCAM is associated
with MLC1 or because the coassembly dissolves during
membrane protein solubilization. We confirmed the inter-
action between GlialCAM and MLC1 in reverse affinity
purification experiments by using an antibody against
GlialCAM that specifically coimmunoprecipitated Glial-
CAM and MLC1 from brain membranes. In the reverse
purification, nearly all MLC1 was associated with Glial-
CAM (Figure 1D). Coimmunoprecipitation experiments
with extracts from cells transfected with both genes also
showedpositive interaction (Figure S2B), indicating a direct
interaction between the proteins. These findings made
HEPACAM an excellent candidate gene for MLC patients
without MLC1 mutations.HEPACAMMutations in MLC Patients without MLC1
Mutations
We analyzed the exons and surrounding intronic regions
of HEPACAM in 40 patients from 34 families from around
the world. In ten patients from eight families, we found
two HEPACAM mutations (Table 1). Sequence analysis of
HEPACAM in the parents showed autosomal-recessive
inheritance of the two mutations in all cases except for
one family with a de novo mutation. None of the patients
had two mutations that abrogate expression of GlialCAM.
In 18 patients from 16 families, we found one HEPACAM
mutation, which was either inherited from a parent or
arose de novo (Table 1). In 12 patients from ten families,
we did not find HEPACAM mutations.
The observed nucleotide changes in HEPACAM are most
likely pathogenic. They were not observed in 400 control
chromosomes. All missense mutations affect amino acids
that are conserved across a wide range of species (Fig-
ure 2B). Nine missense mutations affect amino acids in
the predicted immunoglobulin domains in the extracel-
lular part of GlialCAM (Figures 2A and 2C). p.Pro148Ser
affects a residue between the two immunoglobulin
domains. All these amino acid substitutions are predicted
to affect protein function (SIFT). The substitution of
residue Leu23 by His is predicted to affect the signal
peptide, which spans the first 33 amino acids (SignalP
3.0 Server). Patient EL775 had two missense mutations,
both inherited from the father. p.Asp128Asn is probably
the pathogenic mutation because it is also observed in
patients EL158 and EL708.
In 12 patients from ten families, neither MLC1 nor
HEPACAM mutations were found. In these families, we
could not exclude linkage with both the MLC1 and
HEPACAM loci with certainty (data not shown). The possi-
bility of hidden MLC1 or HEPACAM mutations cannot,
therefore, be excluded, and it is not certain that there
must be a third gene mutated in MLC.erican Journal of Human Genetics 88, 422–432, April 8, 2011 425
Table 1. HEPACAM Mutations
Patient Exon DNA Protein P/M/de novoa
Two Mutations
EL84/85 3 c.587C>A p.Ser196Tyr Pb
4 c.789G>A p.Trp263X M
EL106 3 c.580 delC,
582C>T (hom)
p.Leu194PhefsX60 P þ M
EL125 3 c.442C>T
(hom)
p.Pro148Ser P þ M
EL726 2 c.275G>A p.Arg92Gln P
3 p.631G>A p.Asp211Asn M
EL774 2 c.292C>T
(hom)
p.Arg98Cys –c
EL785 1 c.68T>A p.Leu23His de novo
c.461_462 del p.Ser154TyrfsX16 Pd
4 c.742G>T p.Gly248X Pd
EL816 3 c.442C>T
(hom)
p.Pro148Ser PþM
EL889/890 2 c.292C>T
(hom)
p.Arg98Cys PþM
One Mutation
EL128 2 c.265G>A p.Gly89Ser de novo
EL158 2 c.382G>A p.Asp128Asn Pe
EL604 2 c.265G>A p.Gly89Ser P
EL611 2 c.274C>T p.Arg92Trp M
EL624/625 2 c.274C>T p.Arg92Trp M
EL683/684 2 c.265G>A p.Gly89Ser P
EL686 2 c.266G>A p.Gly89Asp P
EL700 2 c.274C>T p.Arg92Trp –
EL708 2 c.382G>A p.Asp128Asn –
EL743 2 c.274C>T p.Arg92Trp M
EL775 2 c.382G>A p.Asp128Asn Pd
5 c.862C>T p.Arg288Cys Pd
EL847 2 c.404_406 del p.Lys135 del P
EL862 2 c.265G>A p.Gly89Ser M
EL882 2 c.265G>A p.Gly89Ser de novo
EL903 2 c.265G>A p.Gly89Ser Me
EL944 2 c.274C>T p.Arg92Trp de novo
a P, paternal; M, maternal; bold and italic indicates macrocephaly.
b Probably from father but no DNA available.
c No DNA of the parents available.
d Both changes from same parental allele.
e Transient macrocephaly.Inheritance, Phenotypes, and Mutations
All ten patients with twoHEPACAMmutations inherited in
an autosomal-recessive fashion had the classical pheno-
type (Table S2). They had infantile-onset macrocephaly
and delayed-onset motor deterioration, epilepsy, and426 The American Journal of Human Genetics 88, 422–432, April 8, 2cognitive decline of variable severity. The MRI showed
typical white matter abnormalities in all stages of the
disease (Figure S1). The parents were normal, but two of
the 16 had macrocephaly (Table 1).
All 18 patients with one HEPACAM mutation had the
improving phenotype (Table S3). They developedmacroce-
phaly within the first year. In two of the 18, the head
circumference subsequently normalized. The motor capa-
bilities became normal or almost normal. Some patients
had normal intelligence, and others, with intelligence quo-
ficients (IQs) between 50 and 75, had a stable mental retar-
dation. Three of the mentally retarded patients also had
autism or pervasive developmental disorder not otherwise
specified according to DSM IV criteria. In summary, 11 of
the 18 patients became clinically normal, apart from mac-
rocephaly. MRI initially showed typical abnormalities but,
on follow up, major improvement or normalization
(Figure S1). For 13 patients from 11 families, eight of the
11 parents with the mutated allele had macrocephaly,
one had transient macrocephaly as a child, and two never
had macrocephaly as far as they could remember.
Regarding the five remaining patients, the HEPACAM
mutation arose de novo in three, and their parents had
normal head circumference; DNA of the parents was not
available in two. Only one of the parents without the
mutated allele had macrocephaly. The family data suggest
autosomal-dominant inheritance for the single HEPACAM
mutations with variable penetrance. An analysis of micro-
satellite markers near HEPACAM in the families with the
two most common dominant mutations (p.Gly89Ser and
p.Arg92Trp) revealed no shared haplotype, excluding the
possibility of founder effects for these two mutations
(data not shown).
The HEPACAM mutations were either recessive or
dominant. The recessive mutations were spread over the
extracellular region of GlialCAM, whereas the dominant
mutations were clustered in one of the predicted immuno-
globulin-like domains (Figure 2C). Molecular modeling of
the extracellular domain of GlialCAM showed that domi-
nant mutations are located in a putative interface of the
first immunoglobulin domain (Figure 2D).
GlialCAM-MLC1 Interaction
Immunohistochemistry of human brain tissue demon-
strated GlialCAM expression mainly around blood vessels
(Figure 3 and Figure S3). Double immunostaining with
amonoclonal antibody against GlialCAM and a polyclonal
antibody against human MLC113 showed that MLC1 and
GlialCAM colocalize at astrocytic end-feet (Figure 3A). Im-
munogold EM confirmed this colocalization in astrocyte-
astrocyte junctions (Figure 3B).
GlialCAM mRNA and protein have been detected in
oligodendrocytes, astrocytes,18 and neurons19 (Figure S3),
whereas MLC1 has not been detected in oligodendro-
cytes.5–7,20 In MLC, vacuolation mainly affects the outer
layers of myelin sheaths.2 We investigated whether
GlialCAM is localized inmyelin. EM immunogold revealed011
Figure 2. Genetic Studies in MLC Patients
(A) Schematic representation of domains in GlialCAM and position of missense mutations. The positions of several domains in human
GlialCAMwere predicted with PFAM, SOSUI, and SignalP 3.0. The following abbreviations are used: SP, signal peptide; TMM, transmem-
brane domain; Ig, Immunoglobulin. The missense mutations found in MLC patients are indicated above (dominant, in pink) and below
(recessive, in blue) the figure.
(B) Conservation of affected amino acids. GlialCAMprotein sequences were alignedwith ClustalW software. The amino acids affected by
missense mutations are indicated by a gray bar. The position of the affected residues in the human sequence is given above the
sequences. NCBI accession numbers: Homo sapiens, NP_689935.2; Pan troglodytes, XP_522240.2; Bos taurus, NP_001026929.1; Canis
familiaris, XP_852267.1; Mus musculus, NP_780398.2; Monodelphis domestica, XP_001371494.1; Danio rerio, NP_001018526.1. En-
sembl protein ID: Xenopus tropicalis, ENSXETP00000008539.
(C) Schematic model of the protein GlialCAM. The structural model of the extracellular domain was accomplished with the automated
homology-modeling server of the ExPASy server. Mutated residues are depicted with the same color-code as in (A).
(D) Stereo view of a ribbon representation viewed from the top of a structural model of the extracellular domain of GlialCAM. Pink high-
lights the residues mutated in dominant MLC, and blue highlights the residues in recessive MLC. Dominantly mutated residues are
located in the putative extracellular-binding pocket, suggesting that it might mediate protein-ligand interactions.particles inside axons, in contact regions between myelin
and axons, and surrounding myelin (arrows in Fig-
ure 3C). In human medulla oblongata sections, where
axons and myelin can be observed easily, immunostain-
ings combining antibodies against GlialCAM with anti-
bodies against neurofilament heavy chain (NF-H) or
myelin basic protein (MBP) demonstrated that GlialCAM
and NF-H staining coincide in axons (Figures 3D and 3E)
and that not only is GlialCAM observed on the outside
of myelin sheaths (inset in Figure 3E), but there is also
a weak colocalization with MBP in myelin (Figure 3F).
Classical biochemical fractionation protocols to purify
myelin14 and immunoblotting to detect specific proteins
revealed GlialCAM but not MLC1 in the myelin fraction
(Figure 3G).The AmThe effect of mutations located in the extracellular
domain of GlialCAM was studied in cultures of primary
astrocytes, the cell type with the highest natural abun-
dance of both MLC1 and GlialCAM. After adenoviral-
mediated expression, lysates of astrocytes were analyzed
by immunoblot and immunofluorescence. Expression
levels of all types of mutant GlialCAMwere not statistically
different from wild-type GlialCAM (Figure S4). Immuno-
fluorescence revealed that MLC1 and GlialCAM are located
in cell-cell junctions between astrocytes (Figure 4A). Coex-
pression of wild-type MLC1 and GlialCAM containing the
recessive mutations p.Arg92Gln or p.Arg98Cys resulted in
diffuse intracellular MLC1 and GlialCAM localization with
partial enrichment in cell membranes but not specifically
in cell junctions (Figure 4B and Figure S5A). No defecterican Journal of Human Genetics 88, 422–432, April 8, 2011 427
Figure 3. Colocalization of MLC1 and
GlialCAM in Brain Tissue
(A) Double-immunolabeling experiments
in human cerebellum, combining Glial-
CAM (in green) with MLC1 (in red), shows
nearly complete colocalization (Merge, in
yellow) in astrocytic processes surrounding
a blood vessel.
(B) Double-immunolabeling EM shows
colocalization of MLC1 (18 nm gold parti-
cles) and GlialCAM (with a commercially
available monoclonal antibody; 12 nm
gold particles, arrows) in astrocyte-astro-
cyte junctions in human tissue.
(C) Postembedding staining of GlialCAM
in human cerebellum also shows immuno-
reactivity (arrows) inside axons, in contact
regions between myelin and axons, and in
cells that surround myelin.
(D–F) Localization of GlialCAM in human
medulla oblongata. Using the polyclonal
rabbit antibody, we detected GlialCAM in
astrocytes surrounding blood vessels
(arrowheads in D and E), in axons, and in
myelin (arrows in inset in E and in F).
Double immunolabeling of GlialCAM and
NF-H, which stains axons, confirmed co-
localization of GlialCAM and NF-H (yellow
staining in E). The dashed line in E indi-
cates the area amplified in the inset.
Double immunolabeling of GlialCAM and
MBP, which stains myelin, demonstrated
a weak labeling of GlialCAM in myelin.
(G)Myelin was purified from brains of 6- to
8-month-old mice as described in the
Material and Methods. Twenty microgram
of the initial homogenate (H) and of
myelin (M) were analyzed by SDS-PAGE
and immunoblotting. Blots were probed
with antibodies against MBP, GFAP,
MLC1, and GlialCAM. The amount of
GFAP detected in the myelin fraction was
low as compared to the homogenate, indi-
cating that the contamination of the
myelin fraction with nonmyelin proteins
was low. The following abbreviations are
used: AST, astrocyte; MBP, myelin basic
protein; GFAP, glial fibrillary acid protein;
NF-H, neurofilament heavy chain; M,
myelin; A, axon.
The scale bars indicate 50 mm (A and D),
500 nm (B and C), and 10 mm (F).was found for the mutation p.Ser196Tyr (Figure S5C).
Similar mislocalization of MLC1 and GlialCAM was ob-
served after coexpression of wild-typeMLC1 andGlialCAM428 The American Journal of Human Genetics 88, 422–432, April 8, 2011containing the dominant mutations
p.Arg92Trp and p.Gly89Asp (Figures
4D and Figure S5D).
To address the mode of inheritance
of the mutations biochemically, we
performed experiments with equal
levels of wild-type GlialCAM and
GlialCAM containing a dominant or
recessive mutation together withMLC1. The localization of MLC1 and GlialCAM was
analyzed by immunofluorescence. Coexpression of wild-
type GlialCAM rescued the MLC1-trafficking defect caused
Figure 4. MLC1 and GlialCAM Subcel-
lular Localization Changes Caused by
Recessive and Dominant GlialCAM Muta-
tions in Primary Cultures of Astrocytes
(A–F) Astrocytes were coinfected with
adenoviruses expressing MLC1 and wild-
typeGlialCAM (A) orGlialCAMcontaining
a recessive (B, p.Arg92Gln) or a dominant
(D, p.Arg92Trp) MLC-related mutation at
MOI 3. In (C) and (E), cells were coinfected
with MLC1, wild-type GlialCAM, and
GlialCAM containing the indicated muta-
tionat aMOI ratio of 3:2:2.Cellswerefixed,
and permeabilized and then immunofluo-
rescence was performed with a rabbit
polyclonal antibody against human
MLC1 (green) and a monoclonal antibody
detecting GlialCAM protein (red). Nuclei
were stained with DAPI (blue). Colocaliza-
tionbetween thegreenand the red channel
is shown in yellow. Images correspond to
representative cells from four independent
experiments. The scale bars represent
20 mm. (F) Random pictures from different
experiments were taken. Quantification
of the percentage of cells located in junc-
tions (blue), not in junctions (red), or
with a mixed phenotype (yellow, located
partially in junctions and not in junctions)
was performedmanually. Data aremean5
standard error of themeanof four indepen-
dent experiments. Bonferroni’s multiple
comparison test versus in junctions
and not in junctions was used. *p < 0,05;
**p < 0,01; ***p < 0,001. Representative
images for the other mutations shown
in the quantification are depicted in
Figure S5.by GlialCAM with recessive mutations (Figures 4C and 4F
and Figure S5B) but did not rescue the trafficking defect
caused by GlialCAM with dominant mutations (Figures
4E and 4F and Figure S5E). No difference in protein levels
was observed between the mutants and the wild-type
(Figure S4), making it unlikely that the trafficking defect
is due to gene-dosage effects.The American Journal of HumanDiscussion
The leukodystrophy MLC is charac-
terized by infantile-onset macroce-
phaly and delayed neurological dete-
rioration. The diagnosis is based on
MRI criteria.1 In 2001, causative
mutations of MLC were identified in
MLC1, accounting for approximately
75% of the patients. The fact that
genetic-linkage studies failed to iden-
tify a second gene was ascribed to
further genetic heterogeneity.9,10 We
recently identified two presumably
autosomal recessive, phenotypes
among MLC patients without MLC1mutations,11 corroborating the notion of genetic heteroge-
neity. We now show that the genetic heterogeneity does
not involve the gene but the mode of inheritance. We cir-
cumvented the problem of genetic heterogeneity by using
a proteomic approach. This method is validated by the
discovery of HEPACAM (hepatic and glial cell adhesion
molecule, MIM 611642) as a gene disrupted in MLC andGenetics 88, 422–432, April 8, 2011 429
can be considered in the future to identify disease genes for
other rare or genetically heterogeneous disorders.
We prefer the name GlialCAM above HepaCAM for the
related protein. Although the protein was first isolated
from liver and called HepaCAM,21 it was subsequently
found to be predominantly expressed in the central
nervous system and was renamed GlialCAM.18 In the
present paper, we show that mutations in HEPACAM lead
to a neurological phenotype without any sign of liver
involvement.
That mutations in one gene cause both autosomal-
recessive and -dominant disease is rare but not unique.
It has been described for a few other genes, including
LMNA (MIM 150330), SOX18 (MIM 601618), ANK1
(MIM 612641), COL6A1 (MIM 120220), PMP22 (MIM
601097), and MPZ (MIM 159440).22–27 However, patients
with the dominant mutations in these genes do not
display an improving phenotype, as seen in our MLC
patients with dominant HEPACAM mutations. In MLC,
the macrocephaly and cerebral white-matter disease on
MRI arise in the first year of life, the period of most rapid
myelin deposition in the brain. Apparently, MLC1 and
GlialCAM exert their most important function during
this process. The functions of both MLC1 and GlialCAM
are unknown. We, therefore, do not understand the
mechanism of the improving phenotype for the domi-
nant HEPACAM mutations. A hypothetical gene-dose
effect is not supported by the finding that normal
GlialCAM does not partially rescue the localization of
the GlialCAM-MLC1 complex in astrocytes expressing a
dominant HEPACAM mutation. The dominant mutations
are located in a putative pocket of the immunoglobulin
domain and might disrupt interactions with GlialCAM
itself and other unknown molecules.
GlialCAM acts as a MLC1 beta subunit needed for its
correct trafficking to cell-cell junctions. Probably, cis- or
trans-interactions mediated by GlialCAM are necessary
for its correct localization. The function of GlialCAM as
an adhesion molecule suggests that both GlialCAM and
MLC1 have a role in the maintenance of correctly sealed
cell-cell contacts. Interestingly, GlialCAM and not MLC1
is detected in myelin, the place where most vacuoles are
found in MLC.2 GlialCAM is not obligatorily associated
with MLC1, indicating that it might have other functions
by itself or in association with other molecules. Recently, it
has been suggested that MLC1 interacts with the b1
subunit of the Na,K-ATPase pump.28 We did not detect
this protein in our affinity purifications. Further studies
on MLC1-interacting proteins might provide better
insights into the pathophysiology of MLC.
GlialCAM is an interesting protein. In 60% of the
families with dominant HEPACAM mutations, the
affected persons in fact display benign familial macroce-
phaly (MIM 153470). They have macrocephaly, but they
are otherwise normal. MRI shows large but normal
brains. The parents did not undergo MRI as children,
and a transient leukoencephalopathy was not docu-430 The American Journal of Human Genetics 88, 422–432, April 8, 2mented in any of them. Benign familial macrocephaly
is most likely genetically heterogeneous, and HEPACAM
is likely to be one of the related genes. Another inter-
esting finding is that in 40% of the patients with a domi-
nant HEPACAM mutation, macrocephaly, and mental
retardation with or without autism, which are known
to be associated features, persist.29 This clinical
syndrome is probably genetically heterogeneous, and
specific HEPACAM mutations could cause it. The fact
that single HEPACAM mutations might be associated
with different phenotypes requires the geneticist to be
cautious when counseling an affected family. From the
age of approximately 2–3 years, the combination of clin-
ical picture and MRI findings allows an accurate predic-
tion of the phenotype.
In conclusion, we have found that HEPACAM is mutated
in MLC. Recessive mutations cause a progressive leukodys-
trophy that is indistinguishable clinically and byMRI from
the disease caused by recessive MLC1 mutations. Domi-
nant mutations can cause transient clinical and MRI
features of MLC, benign familial macrocephaly, and the
clinical syndrome of macrocephaly andmental retardation
with or without autism.Supplemental Data
Supplemental Data include five figures and three tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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